预约演示

更新于：2025-03-20

Doxycycline Hyclate

盐酸多西环素

更新于：2025-03-20

概要

基本信息

简介盐酸多西环素是一种属于四环素类抗生素药物，商标名称为Vibramycin。最初由辉瑞公司研发并于1967年获得美国食品药品监督管理局(FDA)批准用于治疗多种细菌感染。盐酸多西环素通过与30S核糖体亚基结合，抑制细菌蛋白质合成，阻止细菌生长和扩散。它对广谱的革兰氏阳性和阴性细菌具有细菌抑制活性。该药物以片剂、胶囊和糖浆等不同形式供口服使用。它常用于治疗呼吸道、泌尿道、皮肤和性传播感染，以及眼部感染、莱姆病和疟疾等疾病，与其他药物联合使用效果更佳。

药物类型

小分子化药

别名

D-PLEX、DOXY、Doxycycline Hyclate Tabiets

+ [31]

靶点

30S subunit

作用方式

抑制剂

作用机制

30S subunit抑制剂(30S核糖体亚基抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

CHARTWELL RX SCIENCES LLCMayne Pharma International Pty Ltd.

PolyPid Ltd.

+ [2]

非在研机构

Chartwell Pharma NDA B2 Holdings, LLC.

Den-Mat Holdings LLCPfizer Laboratories (Pty) Ltd.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1967-12-05),

感染

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)、快速通道 (美国)、突破性疗法 (美国)、合格传染病产品 (美国)

登录后查看时间轴

结构/序列

分子式C46H58Cl2N4O18

InChIKeyHALQELOKLVRWRI-VDBOFHIQSA-N

CAS号24390-14-5

查看全部结构式(2)

关联

项与盐酸多西环素相关的临床试验

NCT06683638

/ Recruiting临床2期IIT

Daily Doxycycline for Early Syphillis

The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study aims to answer is:
Is doxycycline taken as a single daily dose of 200mg for 14 days an effective treatment for early syphilis based on a combined outcome of clinical improvement and blood test improvement?
Participants will:
1. Take doxycycline 200mg daily for 14 days
2. Submit oral and rectal swabs that test for syphilis bacteria every other day for 2 weeks, returned by mail
3. Complete 2 brief online surveys over the first 2 weeks
4. Return to the clinic for an interview and blood draw every 3 months for a maximum of 3 study visits, including the first visit
The investigators will compare the percentage of participants in the study who have response to treatment by 6 months to that of persons who have received standard (CDC-recommended) regimens. To do this, the investigators will calculate response percentage estimates following a shot of long-acting penicillin or 14 days of doxycycline 100mg twice daily from 60-person samples from the sexual health program's records.

开始日期2025-03-03

申办/合作机构

University of Washington

CTR20250332

/ Active, not recruitingN/A

盐酸多西环素片随机、开放、交叉设计在中国健康受试者中的生物等效性研究

主要目的：以苏州朗科生物技术股份有限公司的盐酸多西环素片为受试制剂；并以Pfizer Japan Inc.持证的盐酸多西环素片为参比制剂，进行生物等效性正式试验。

开始日期2025-03-03

申办/合作机构

苏州朗科生物技术股份有限公司

NCT06738407

/ Not yet recruiting临床3期

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young People in the United States

The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among people who were assigned female at birth (AFAB) while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.

开始日期2025-02-15

申办/合作机构

Westat, Inc.

[+6]

100 项与盐酸多西环素相关的临床结果

登录后查看更多信息

100 项与盐酸多西环素相关的转化医学

登录后查看更多信息

100 项与盐酸多西环素相关的专利（医药）

登录后查看更多信息

20,165

项与盐酸多西环素相关的文献（医药）

2025-12-01·Current Genetics

Whole-genome evaluation and prophages characterization associated with genome of carbapenem-resistant Acinetobacter baumannii UOL-KIMZ-24-2

Article

作者: Naqvi, Syed Zeeshan Haider ; Saqib, Anam ; Saleem, Sidrah ; Nawaz, Aniqa ; Ali, Hazrat ; Fatima, Kiran ; Ansari, Farheen ; Ahmad, Mushtaq ; Jahan, Shah ; Hassan, Noor

Carbapenem-resistant Acinetobacter baumannii (CRAB) is an emerging threat to healthcare settings in many countries, principally in South Asia. The current study was aimed to identify, evaluate whole-genome and characterize the prophages in genome of CRAB strain, recovered from patients of Lahore General Hospital, Lahore. More than 200 samples were collected and identified by morphological and biochemical tests. These strains were also subjected to a comprehensive antimicrobial susceptibility evaluation using Kirby-Bauer method and further confirmed as CRAB strains by exploring bla_OXA-51. In addition, the whole-genome evaluation of a Acinetobacter baumannii UOL-KIMZ-24-2 was carried out using various Bioinformatics tools. A total of 150 strains of A. baumannii were recovered and identified in the current study. Among them, 49% strains were found resistant to carbapenem. The bla_OXA-51 was found prevalent in the genome of A. baumannii recovered from medical ICU (38%). In addition, the UOL-KIMZ-24-2 genome analysis based on multilocus sequence typing (MLST) highlighted that UOL-KIMZ-24-2 belonged to ST2 (Pasteur scheme) sequence type. A total of 29 antimicrobial resistance (AMR) genes were present, importantly, bla_OXA-66, bla_OXA-23 and bla_OXA-25. The mobile genetic elements (MGEs) were identified as transposases and belonged to four classes e.g. IS15d1, ISAba24, ISEc29, and ISEc35. A total of 14 virulence factors encoded by 58 different genes were detected in UOL-KIMZ-24-2. In addition, the phage sequences were identified in genome of UOL-KIMZ-24-2, divided into 3 regions. In conclusion, UOL-KIMZ-24-2 contained a mixture of AMR genes, MGEs. prophages sequences and virulence genes.

2025-07-01·Separation and Purification Technology

Carbon defects engineered for the formation of highly stable single-atom Pt-N3 bonds: Enhanced electron transfer and efficient peroxymonosulfate activation

作者: Zhong, Haoxiang ; Tan, Xiaofei ; Xu, Piao ; Xu, Jialu ; Hu, Xi ; Yuan, Yuxin ; Zhang, He ; Zhu, Shanshan ; Lai, Cui ; Tang, Chunfang ; Hu, Xinjiang ; Wang, Hui

In this study, a highly stable single-atom Pt-dispersed carbon-deficient graphitic carbon nitride (Pt_SAC/G-CN) photocatalyst with a Pt-N₃ coordination structure was synthesized (supported by X-ray absorbing near-edge structures).The incorporation of Pt atoms altered the electron distribution within the carbon-defective g-C₃N₄ (G-CN), forming a Pt-N₃ coordination structure.This Pt-N₃ coordination structure enhanced the electron transfer efficiency of the photocatalyst, which improved the activation of peroxymonosulfate (PMS) and subsequently facilitated the generation of reactive free radicals.Pt_0.1/G-CN efficiently activated PMS under visible light (λ > 400 nm), resulting in a ciprofloxacin (CIP) degradation of 96.1 % within 150 min.Notably, the turnover frequency (TOF) of Pt_0.1/G-CN is as high as 0.125 min^-1, which is 2-3 orders of magnitude higher than normal Pt-containing catalysts for CIP degradationRadicals quenching experiments and ESR (EPR) indicated that •OH playing crucial roles in the CIP degradation process.Pt_0.1/G-CN exhibited excellent stability and reusability, further emphasizing its practical application potential.Moreover, the role and mechanism of platinum atoms in efficiently activating PMS and degrading quinolone antibiotics under visible light irradiation were also elucidated.These findings provided novel insights into the design of stabilized single-atom metal catalysts for practical use, offering a feasible approach for environmental pollution remediation.

2025-06-01·Materials Research Bulletin

Study on the influence of solvent type on the morphology and properties of BiOBr nanosheets through the photodegradation of Doxycycline

作者: Van Huynh, Tien ; Nguyen, Oanh T. K. ; Nguyen, Vi T. T.

The BiOBr photocatalysts with varied morphologies were prepared utilizing the solvothermal approach with solvents.The effects of different solvents on the characteristics and morphol. of BiOBr materials were investigated in depth.The photocatalytic activity of the as-synthesized BiOBr samples was determined by their capacity to degrade Doxycycline (DC) under visible light.The quenching tests revealed that ^•O₂^- and e^- have played a significant role in DC degradationAt a DC concentration of 15 ppm, the BiOBr catalyst, which was produced by dissolving bismuth nitrate in isopropanol, achieved a degrading efficiency of approx. 80%.Reuse studies, together with X-ray diffraction (XRD) and SEM (SEM) examinations of before and after catalysts, validated the reusability and enhanced stability of the as-prepared material.Furthermore, liquid chromatog.-tandem mass spectrometry (LC-MS/MS) was used to determine the degradation routes of DC intermediates, and toxicity studies were carried out using quant. structure-activity relationship (QSAR) modeling.

138

项与盐酸多西环素相关的新闻（医药）

2025-03-18

·PRNewswire

Low Doses of Antibiotic Work Just as Well as Higher Ones to Treat Rare Type of Chronic Hair Loss

NEW YORK, March 18, 2025 /PRNewswire/ -- Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss, a new study shows. This regimen may also come with fewer side effects than higher doses of the medication. Continue Reading Led by researchers at NYU Langone Health, the study explored lymphocytic scarring alopecia, a rare skin condition in which the body's immune cells damage hair follicles, leading to hair loss and scarring. Physicians typically treat this chronic disorder with relatively high doses of the antibiotic doxycycline, often for prolonged periods of time. However, the drug can trigger nausea, vomiting, and rashes and may discourage patients from continuing to take it, the study authors say. As a result, the team set out to determine whether lower doses could work instead. Besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Post this The findings in 241 men and women treated for several forms of lymphocytic scarring alopecia revealed that lower doses (usually 20 milligrams taken twice daily) and higher doses (as much as 100 milligrams taken twice daily) of doxycycline were equally effective. Specifically, the researchers found no significant difference between the two groups on evaluations of scalp inflammation, patients' perception of the severity of their hair loss, and clinical measurements of hair density, hair-shaft diameter, and hairline recession. In addition, while 23% of those on the high-dose regimen experienced common negative side effects of doxycycline, only 12% of those taking smaller doses of the drug did so. Another key finding was that while 25% of the high-dose group stopped taking doxycycline altogether due to gastrointestinal issues, only 16% of the low-dose group stopped treatment due to this side effect. "Our findings suggest that physicians can prescribe lower doses of doxycycline to patients struggling with lymphocytic scarring alopecia without compromising the efficacy and anti-inflammatory benefit of the therapy," said study co-lead author Carli Needle, BA. Needle, a medical student at NYU Grossman School of Medicine, adds that besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Doxycycline, she notes, is known to harm the helpful bacteria that live in the digestive tract and bolster the body's defenses against disease-causing microbes. However, past studies have shown that drug doses below 40 milligrams are less risky for beneficial microbes. The new study is the first to directly compare the efficacy of different-size doses of doxycycline to treat lymphocytic scarring alopecia, says Needle. A report on the findings is publishing March 18 in the Journal of the American Academy of Dermatology. For the study, the research team collected data from electronic medical records of patients with scarring alopecia treated at NYU Langone Health between 2009 and 2023. Of these, about 27% had been prescribed low doses of doxycycline and nearly 73% were on traditional high-dose regimens. Next, the team ran a statistical analysis to compare the two groups. The researchers discounted from their analysis any effects of other medications that commonly accompany this treatment, such as the hair-growth drug minoxidil. According to the authors, a further advantage of reducing doxycycline doses is that experts have linked the drug to the rise of dangerous bacterial populations that can survive antibiotic treatments. Clinicians worldwide are now seeking to combat such antibiotic resistance by limiting how often and in what quantities they prescribe these drugs, a practice called antibiotic stewardship. "Our results offer another avenue for healthcare providers to protect patients from harm caused by unnecessary antibiotic use and address the rise of drug-resistant strains of microbes," said study co-lead author Anna Brinks, BA, a medical student at NYU Grossman School of Medicine. "Alopecia can have a devastating effect on self-image and can lead to social judgment, depression, and anxiety," added study co-senior author Kristen Lo Sicco, MD. "Studies that advance the management of these conditions are critical to addressing not only hair loss itself, but also the psychological and social consequences that accompany it." Lo Sicco, an associate professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, says that the researchers next plan to repeat their work in a larger and more diverse group, as the study patients were mostly White. In addition, she says the team intends to explore the triggers that cause lymphocytic scarring alopecia, which remain poorly understood. Study funding was provided by NYU Langone Health. In addition to Needle, Brinks, and Lo Sicco, other NYU Langone researchers involved in the study are Akshay Pulavarty, MD, MPH; Caitlin Kearney, BS; Ambika Nohria, BA; Deesha Desai, BS; and Jerry Shapiro, MD. About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone the No. 1 comprehensive academic medical center in the country for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 300 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise with over $1 billion in active awards from the National Institutes of Health. Media Inquiries: Shira Polan Phone: 212-404-4279 [email protected] SOURCE NYU Grossman School of Medicine and NYU Langone Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

2025-03-11

·GlobeNewswire-Health Care

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy DesignationsPETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. This milestone follows recommendation by the independent Data Safety Monitoring Board (“DSMB”), which, after analyzing unblinded efficacy data from the first 430 enrolled patients in the trial, recommended concluding the study upon enrollment of 800 patients, the lowest sample size reassessment stop after the minimum planned number of patients. The Company anticipates reporting top-line results by the end of the second quarter of 2025. If the Phase 3 data are positive, PolyPid expects to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”), leveraging the FDA’s Fast Track and Breakthrough Therapy designations. “We are excited to reach another critical milestone in our ongoing SHIELD II Phase 3 trial, reinforcing the positive trajectory of D-PLEX100’s development,” said Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “With top-line data expected by the end of the second quarter of 2025, we are preparing to engage with the FDA for a pre-NDA meeting to discuss a rolling NDA submission under the Breakthrough Therapy designation. Importantly, we remain in active discussions with multiple potential partners for the commercialization of D-PLEX100 in various regions, starting with the U.S.” About SHIELD IISHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care (“SoC”), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a surgical site infection (“SSI”) event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel. About D-PLEX100D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA for the prevention of SSIs in patients undergoing abdominal colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing of anticipated reporting of top-line results, that upon potential positive Phase 3 data, the Company anticipates submission of an NDA leveraging the advantages of Fast Track and Breakthrough Therapy designations, the intention to pursue a pre-NDA meeting with the FDA to discuss a rolling NDA submission, and discussions with multiple potential partners for the commercialization of D-PLEX100 in various regions, starting with the U.S. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@lifesciadvisors.com

临床3期快速通道申请上市合格传染病产品突破性疗法

2025-03-09

·信狐药迅

乐普ADC重磅产品注射用维贝柯妥塔单抗主动撤回后第二次提交上市申请|新受理（3.3-3.9）

本周药品注册受理数据，分门别类呈现，一目了然。(3.3-3.9）新药上市申请药品名称企业注册分类受理号丁二酸复瑞替尼胶囊复星万邦(江苏)医药集团有限公司1CXHS2500021注射用维贝柯妥塔单抗乐普生物科技股份有限公司1CXSS2500034 新药临床申请药品名称企业注册分类受理号DZD8586片迪哲(江苏)医药股份有限公司1CXHL2500261HRS9531注射液福建盛迪医药有限公司1CXHL2500260HRS9531注射液福建盛迪医药有限公司1CXHL2500259TRD205片北京泰德制药股份有限公司1CXHL2500254TRD205片北京泰德制药股份有限公司1CXHL2500253PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500257PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500256PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500255奎斯诺片中科南京生命健康高等研究院1CXHL2500245HS-10510片江苏豪森药业集团有限公司1CXHL2500244HS-10510片江苏豪森药业集团有限公司1CXHL2500243MWN109片上海民为生物技术有限公司1CXHL2500241MWN109片上海民为生物技术有限公司1CXHL2500240MWN109片上海民为生物技术有限公司1CXHL2500239SGB-3383注射液苏州圣因生物医药有限公司1CXHL2500238MWN109片上海民为生物技术有限公司1CXHL2500237MWN109片上海民为生物技术有限公司1CXHL2500236MWN109片上海民为生物技术有限公司1CXHL2500235MWN109片上海民为生物技术有限公司1CXHL2500234MWN109片上海民为生物技术有限公司1CXHL2500242KEM2403注射液深圳珐玛易药品科技有限公司2.1CXHL2500258KEM2418缓释直服颗粒深圳珐玛易药品科技有限公司2.2CXHL2500252利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500250利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500249利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500248利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500247利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500246优替德隆胶囊成都华昊中天药业有限公司2.2;2.4CXHL2500251SMF-217江西施美药业股份有限公司2.3CXHL25002336价B族链球菌结合疫苗苏州聚微生物科技有限公司1.1CXSL2500190LVRNA015珠海丽凡达生物技术有限公司1.2CXSL2500208重组带状疱疹疫苗(CHO细胞)长春百克生物科技股份公司1.3CXSL2500213ACYW135X群脑膜炎球菌多糖结合疫苗北京科兴中维生物技术有限公司1.4CXSL2500200注射用JS203上海君实生物医药科技股份有限公司1CXSL2500212SH006注射液南京圣和药业股份有限公司1CXSL2500211BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500210BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500209SHR-4712注射液广东恒瑞医药有限公司1CXSL2500207SHR-4712注射液广东恒瑞医药有限公司1CXSL2500206注射用CS2009申石生物医药(上海)有限公司1CXSL2500205IMM27M注射液宜明昂科生物医药技术(上海)股份有限公司1CXSL2500204TQB2930注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2500203TQB2930注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2500202CM336注射液康诺亚生物医药科技(成都)有限公司1CXSL2500201注射用重组人源化抗BCMA/CD3双特异性抗体山东新时代药业有限公司1CXSL2500199FB1002重组人源化单克隆抗体注射液福贝生物医药科技(北京)有限公司1CXSL2500192REGEND003细胞自体回输制剂上海吉锐医学科技有限公司1CXSL2500196皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500195皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500194皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500193注射用FP008珠海菲鹏制药有限公司1CXSL2500191注射用BGB-B455广州百济神州生物制药有限公司1CXSL2500198NTB003注射液南京正大天晴制药有限公司1CXSL2500197 仿制药申请药品名称企业注册分类受理号盐酸丁螺环酮片河北龙海药业有限公司3CYHS2500983盐酸多沙普仑注射液成都瑞尔医药科技有限公司3CYHS2500976盐酸普罗帕酮注射液南阳普康恒旺药业有限公司3CYHS2500968盐酸异丙肾上腺素注射液绪必迪药业(沧州)有限公司3CYHS2500967维生素K滴剂四川海梦智森生物制药有限公司3CYHS2500965盐酸多巴酚丁胺注射液武汉市金恒泰药业有限公司3CYHS2500964盐酸美金刚口腔崩解片合肥恩瑞特药业有限公司3CYHS2500954盐酸美金刚口腔崩解片合肥恩瑞特药业有限公司3CYHS2500953溴吡斯的明片吉林省博大伟业制药有限公司3CYHS2500951西格列汀二甲双胍缓释片河北天成药业股份有限公司3CYHS2500941盐酸溴己新口服溶液北京双鹭药业股份有限公司3CYHS2500940维生素B6注射液汇禹远和(海南)药业有限公司3CYHS2500939洛索洛芬钠口服溶液浙江高跖医药科技股份有限公司3CYHS2500933醋酸特利加压素注射液成都天台山制药股份有限公司3CYHS2500927福多司坦口服溶液江苏润恒制药有限公司3CYHS2500925美洛昔康纳米晶注射液扬子江药业集团有限公司3CYHS2500924洛索洛芬钠口服溶液安徽杰玺医药有限公司3CYHS2500923聚乙二醇3350散合肥盛秦医药科技有限公司3CYHS2500920法莫替丁注射液南京正科医药股份有限公司3CYHS2500914法莫替丁注射液南京正科医药股份有限公司3CYHS2500913盐酸多西环素片德全药品(江苏)股份有限公司3CYHS2500910醋氯芬酸片合肥英太制药有限公司3CYHS2500909艾曲泊帕乙醇胺干混悬剂湖北民康药业集团有限公司3CYHS2500908硫代硫酸钠注射液苏州朗科生物技术股份有限公司3CYHS2500905硫代硫酸钠注射液苏州朗科生物技术股份有限公司3CYHS2500904硝普钠注射液康普药业股份有限公司3CYHS2500903醋酸地非法林注射液齐鲁制药(海南)有限公司3CYHS2500902头孢地尼干混悬剂广东万泰科创药业有限公司3CYHS2500901碳酸司维拉姆干混悬剂中美华世通生物医药科技(武汉)股份有限公司3CYHS2500900碳酸司维拉姆干混悬剂中美华世通生物医药科技(武汉)股份有限公司3CYHS2500899熊去氧胆酸颗粒辽宁海一制药有限公司3CYHS2500897阿瑞匹坦注射液石药集团中诺药业(石家庄)有限公司3CYHS2500896葡萄糖酸钙氯化钠注射液湖北津药药业股份有限公司3CYHS2500895阿昔莫司胶囊安徽佳和药业有限公司4CYHS2500986来特莫韦注射液石家庄四药有限公司4CYHS2500985盐酸贝尼地平片石家庄四药有限公司4CYHS2500984比索洛尔氨氯地平片山东益康药业股份有限公司4CYHS2500982培哚普利氨氯地平片(III)南京海纳制药有限公司4CYHS2500981蒙脱石混悬液湖北午时药业股份有限公司4CYHS2500980布洛芬混悬液珠海联邦制药股份有限公司4CYHS2500979注射用紫杉醇(白蛋白结合型)浙江圣兆药物科技股份有限公司4CYHS2500978厄贝沙坦氢氯噻嗪片天津华津制药有限公司4CYHS2500977洛索洛芬钠凝胶贴膏湖北民康药业集团有限公司4CYHS2500975沙库巴曲缬沙坦钠片辽宁鑫善源药业有限公司4CYHS2500974沙库巴曲缬沙坦钠片辽宁鑫善源药业有限公司4CYHS2500973沙库巴曲缬沙坦钠片辽宁鑫善源药业有限公司4CYHS2500972甲磺酸沙非胺片上海上药中西制药有限公司4CYHS2500971甲磺酸沙非胺片上海上药中西制药有限公司4CYHS2500970硫酸氨基葡萄糖胶囊安徽佳和药业有限公司4CYHS2500969甲磺酸倍他司汀片北京紫萌医药科技有限公司4CYHS2500966沙库巴曲缬沙坦钠片江苏中邦制药有限公司4CYHS2500963沙库巴曲缬沙坦钠片江苏中邦制药有限公司4CYHS2500962酮洛芬凝胶苏州高迈药业有限公司4CYHS2500961依达拉奉氯化钠注射液福建天泉药业股份有限公司4CYHS2500960瑞舒伐他汀依折麦布片(I)浙江京新药业股份有限公司4CYHS2500959盐酸羟考酮缓释片北京华素制药股份有限公司4CYHS2500958注射用硫酸艾沙康唑南京易亨制药有限公司4CYHS2500956氢溴酸替格列汀片浙江诺得药业有限公司4CYHS2500955硝酸异山梨酯注射液江苏润恒制药有限公司4CYHS2500952盐酸奥布卡因滴眼液海南斯达制药有限公司4CYHS2500950布瑞哌唑片山东鲁抗医药股份有限公司4CYHS2500949布瑞哌唑片山东鲁抗医药股份有限公司4CYHS2500948布瑞哌唑片山东鲁抗医药股份有限公司4CYHS2500947左乙拉西坦口服溶液江苏润恒制药有限公司4CYHS2500946盐酸二甲双胍片石家庄市普力制药有限公司4CYHS2500945盐酸二甲双胍片石家庄市普力制药有限公司4CYHS2500944玻璃酸钠滴眼液润尔眼科药物(广州)有限公司4CYHS2500943美阿沙坦钾片珠海润都制药股份有限公司4CYHS2500957硫酸镁钠钾口服用浓溶液湖北民康药业集团有限公司4CYHS2500938左乙拉西坦片北京世桥生物制药有限公司4CYHS2500937左乙拉西坦片北京世桥生物制药有限公司4CYHS2500936卡泊三醇软膏东阳祥昇医药科技有限公司4CYHS2500935西格列汀二甲双胍片(Ⅱ)北京元延医药科技股份有限公司4CYHS2500934氟比洛芬凝胶贴膏浙江高跖医药科技股份有限公司4CYHS2500932洛索洛芬钠凝胶贴膏浙江高跖医药科技股份有限公司4CYHS2500942巴瑞替尼片广州绿十字制药股份有限公司4CYHS2500931巴瑞替尼片广州绿十字制药股份有限公司4CYHS2500930聚多卡醇注射液广东万泰科创药业有限公司4CYHS2500929聚多卡醇注射液广东万泰科创药业有限公司4CYHS2500928莫匹罗星软膏湖北科田药业有限公司4CYHS2500926依折麦布辛伐他汀片浙江亚瑟医药有限公司4CYHS2500922吗啉硝唑氯化钠注射液安徽威尔曼制药有限公司4CYHS2500921聚多卡醇注射液哈尔滨誉衡制药有限公司4CYHS2500919聚多卡醇注射液哈尔滨誉衡制药有限公司4CYHS2500918聚多卡醇注射液哈尔滨誉衡制药有限公司4CYHS2500917乙酰半胱氨酸颗粒海南海神同洲制药有限公司4CYHS2500912乙酰半胱氨酸颗粒海南海神同洲制药有限公司4CYHS2500911小儿法罗培南钠颗粒江苏睿实生物科技有限公司4CYHS2500907甲硝唑凝胶湖北舒邦药业有限公司4CYHS2500906硫酸艾沙康唑胶囊广州市联瑞制药有限公司4CYHS2500916氧(液态)淄博鲁川气体有限公司4CYHS2500915地屈孕酮片河南泰丰生物科技有限公司4CYHS2500898布洛芬混悬液华益药业科技(安徽)有限公司4CYHS2500894氧(液态)沁阳京宇气体有限公司4CYHS2500893咪达唑仑鼻喷雾剂四川普锐特药业有限公司3CYHL2500057厄贝沙坦氨氯地平片杭州沐源生物医药科技有限公司3CYHL2500056瑞卢戈利片山西振东制药股份有限公司3CYHL2500055 进口申请药品名称企业注册分类受理号来特莫韦微片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.5.1JXHS2500036来特莫韦微片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.5.1JXHS2500035古塞奇尤单抗注射液Janssen-Cilag International NV2.2JXSS2500022伊奈利珠单抗注射液Horizon Therapeutics Ireland DAC2.2JXSS2500021布瑞哌唑片Hetero Labs Limited, Unit-V5.2JYHS2500013布瑞哌唑片Hetero Labs Limited, Unit-V5.2JYHS2500012布瑞哌唑片Hetero Labs Limited, Unit-V5.2JYHS2500011BMS-986365胶囊Celgene Corporation1JXHL2500036BI 1291583 片Boehringer Ingelheim International GmbH1JXHL2500035PF-06821497片Pfizer Inc.1JXHL2500034PF-06821497片Pfizer Inc.1JXHL2500033PF-07275315注射液Pfizer Inc.1JXSL2500035CagriSema注射液Novo Nordisk A/S1JXSL2500034CagriSema注射液Novo Nordisk A/S1JXSL2500033CagriSema注射液Novo Nordisk A/S1JXSL2500032CagriSema注射液Novo Nordisk A/S1JXSL2500031CagriSema注射液Novo Nordisk A/S1JXSL2500030PIT565Novartis Pharma AG1JXSL2500029 中药相关申请无注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗抗体药物偶联物申请上市临床申请

100 项与盐酸多西环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸多西环素	J01AA02 A01AB22	DB00254

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿米巴痢疾	美国	Mayne Pharma International Pty Ltd.	2013-04-11
吸入炭疽	美国	Mayne Pharma International Pty Ltd.	2013-04-11
性传播疾病	美国	Mayne Pharma International Pty Ltd.	2013-04-11
包涵体性结膜炎	美国	Mayne Pharma International Pty Ltd.	2005-05-06
革兰氏阴性菌感染	美国	Mayne Pharma International Pty Ltd.	2005-05-06
性病性淋巴肉芽肿	美国	Mayne Pharma International Pty Ltd.	2005-05-06
非淋菌性尿道炎	美国	Mayne Pharma International Pty Ltd.	2005-05-06
肺炎支原体感染	美国	Mayne Pharma International Pty Ltd.	2005-05-06
鹦鹉热	美国	Mayne Pharma International Pty Ltd.	2005-05-06
Q热	美国	Mayne Pharma International Pty Ltd.	2005-05-06
回归热	美国	Mayne Pharma International Pty Ltd.	2005-05-06
呼吸道感染	美国	Mayne Pharma International Pty Ltd.	2005-05-06
立克次体感染	美国	Mayne Pharma International Pty Ltd.	2005-05-06
洛矶山斑疹热	美国	Mayne Pharma International Pty Ltd.	2005-05-06
斑点热群立克次体病	美国	Mayne Pharma International Pty Ltd.	2005-05-06
沙眼	美国	Mayne Pharma International Pty Ltd.	2005-05-06
地方性斑疹伤寒	美国	Mayne Pharma International Pty Ltd.	2005-05-06
尿道炎或宫颈炎：沙眼衣原体	美国	Mayne Pharma International Pty Ltd.	2005-05-06
感染	日本	Pfizer Japan, Inc.	1975-04-25
细菌感染	中国	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌感染	申请上市	加拿大	SteriMax, Inc.	2025-01-01
术后感染	临床3期	以色列	PolyPid Ltd.	2020-06-24
手术伤口感染	临床3期	美国	PolyPid Ltd.	2019-12-17
手术伤口感染	临床3期	以色列	PolyPid Ltd.	2019-12-17
术后感染	药物发现	克罗地亚	PolyPid Ltd.	2020-06-24
术后感染	药物发现	捷克	PolyPid Ltd.	2020-06-24
玫瑰痤疮	药物发现	美国	CollaGenex Pharmaceuticals, Inc.	2002-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04233424 (SHIELD 1, Literature) 人工标引	临床3期	手术伤口感染	-	D-PLEX 100+SOC	(襯窪遞衊鬱選糧廠選襯) = 觸簾壓簾範蓋選鬱壓遞積艱淵遞壓齋製鑰觸製 (鏇築觸窪網艱鏇蓋積鑰 )	积极	2024-10-21
				SOC	(襯窪遞衊鬱選糧廠選襯) = 範網顧蓋窪襯壓衊構鹹積艱淵遞壓齋製鑰觸製 (鏇築觸窪網艱鏇蓋積鑰 )
NCT05399290 (CTgov)	临床4期	寻常痤疮	22	Doxycycline Hyclate (100 mg Standard Dose Doxycycline BID)	衊壓糧窪糧築鏇襯遞餘(醖鬱齋壓築範觸齋遞餘) = 衊鬱簾膚膚夢獵簾鹹鏇構衊齋網糧壓襯襯繭淵 (繭淵製鑰餘淵範壓選醖, 製觸簾衊窪襯鑰餘淵齋 ~ 糧選遞鹽鬱鹹選膚膚積) 更多	-	2023-04-03
				Doxycycline Hyclate (20 mg Sub-antimicrobial Dose Doxycycline BID)	衊壓糧窪糧築鏇襯遞餘(醖鬱齋壓築範觸齋遞餘) = 選顧窪衊鬱淵醖鬱廠醖構衊齋網糧壓襯襯繭淵 (繭淵製鑰餘淵範壓選醖, 網簾選構顧憲襯衊獵壓 ~ 憲觸壓憲製觸衊蓋餘齋) 更多
NCT02899000 (CTgov)	临床4期	寻常痤疮	186	Oral doxycycline hyclate+Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel	積夢選顧構顧鏇鏇遞製(構齋膚鏇糧醖夢範鬱製) = 鬱餘齋網鏇壓願顧簾餘積獵醖顧醖憲糧醖醖選 (夢艱壓範廠鏇淵淵願憲, 繭網襯醖網膚襯鬱醖壓 ~ 顧鹽壓願獵築蓋艱網憲) 更多	-	2022-12-09
NCT04233424 (SHIELD I \| D-PLEX 311, Corporate Publications) 人工标引	临床3期	手术伤口感染	423	Standard of Care+D-PLEX100	觸製繭衊繭製範鹹鬱襯(遞範構艱艱蓋淵鹹醖鏇): difference = -54, P-Value = <0.0032	积极	2022-09-02
				Standard of Care
NCT03633123 (Pubmed) 人工标引	临床2期	手术伤口感染	179	SoC+D-PLEX 100	築憲鏇鹽遞餘製醖觸膚(齋製膚窪築淵網襯積糧) = 繭膚糧醖獵膚蓋願選獵鏇願餘觸衊衊醖築鏇鹹 (窪糧選淵淵糧壓鑰衊鹽 )	积极	2022-09-01
				SoC	築憲鏇鹽遞餘製醖觸膚(齋製膚窪築淵網襯積糧) = 積壓鏇鑰襯膚繭積衊網鏇願餘觸衊衊醖築鏇鹹 (窪糧選淵淵糧壓鑰衊鹽 )
NCT03075891 (ANSWER, CTgov)	临床4期	玫瑰痤疮	273	Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules)	製淵顧積鑰餘鏇夢積齋(簾餘廠糧鬱鹽願鑰窪繭) = 襯夢糧鑰製範憲艱願網鑰鹽積選壓憲膚膚衊艱 (範網壓鬱築廠鹹壓築齋, 廠廠餘膚襯繭遞壓鑰鹹 ~ 簾鹹醖觸醖廠獵遞壓壓) 更多	-	2019-11-29
				Oral placebo capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Oral Placebo Capsules)	製淵顧積鑰餘鏇夢積齋(簾餘廠糧鬱鹽願鑰窪繭) = 築選選鬱壓糧願願構簾鑰鹽積選壓憲膚膚衊艱 (範網壓鬱築廠鹹壓築齋, 艱範願艱壓鹽艱獵壓夢 ~ 憲廠顧齋蓋獵網鑰糧製) 更多
NCT00246740 (CTgov)	临床2期	再灌注损伤	56	Placebo Oral Tablet (Placebo Oral Tablet)	鏇繭醖艱壓憲網鹹繭淵(製淵壓網範壓顧蓋範願) = 簾選壓糧淵餘醖鏇鹹鹹網鏇憲願鹽網憲簾窪醖 (醖襯鬱憲鑰願淵膚製壓, 繭鹹鹹簾餘醖蓋顧憲壓 ~ 窪膚選選遞簾衊顧簾鹹) 更多	-	2017-12-15
				Periostat (Periostat)	鏇繭醖艱壓憲網鹹繭淵(製淵壓網範壓顧蓋範願) = 襯餘鹹鹹淵衊觸艱窪夢網鏇憲願鹽網憲簾窪醖 (醖襯鬱憲鑰願淵膚製壓, 構夢鏇鏇鑰築鹽醖選選 ~ 膚願艱醖製積壓積築淵) 更多
NCT01113931 (CTgov)	临床3期	沙眼衣原体感染	495	Doxycycline Hyclate (Doxycycline Hyclate)	(簾顧選鑰構範膚糧繭遞) = 夢製夢鑰膚壓鬱蓋夢壓襯遞簾遞鏇鬱壓顧築鏇 (鹹鏇製醖衊鑰獵襯醖醖, 艱觸獵壓壓鹹醖襯襯遞 ~ 夢齋蓋網觸築淵鹹鹽製) 更多	-	2012-01-27
				Vibramycin (Vibramycin)	(簾顧選鑰構範膚糧繭遞) = 襯簾糧簾齋顧網鏇糧憲襯遞簾遞鏇鬱壓顧築鏇 (鹹鏇製醖衊鑰獵襯醖醖, 顧遞夢膚製鏇憲積夢窪 ~ 壓膚選蓋遞顧襯廠淵繭) 更多
NCT00635609 (CTgov)	临床4期	寻常痤疮	93	Doxycycline Hyclate (Doryx) (Doxycycline Hyclate (Doryx) Delayed-release Tablets)	構繭選製餘鹹鬱衊顧繭(網鬱夢獵獵壓膚範簾築) = 夢壓淵壓齋範簾簾艱築鑰蓋選蓋範蓋簾顧獵鬱 (顧糧網憲觸醖艱鹽選願, 選築窪壓遞衊獵糧構築 ~ 膚願選廠簾鹹製淵遞鏇) 更多	-	2009-12-30
				Doxycycline Hyclate (Doxycycline Hyclate Immediate-release Tablets)	構繭選製餘鹹鬱衊顧繭(網鬱夢獵獵壓膚範簾築) = 選製襯範壓廠醖築積繭鑰蓋選蓋範蓋簾顧獵鬱 (顧糧網憲觸醖艱鹽選願, 齋膚糧鹽繭鹽顧窪鬱鬱 ~ 範廠憲餘築餘鬱壓製糧) 更多